Business Context and Reporting Period
This Form 8-K Current Report was filed by Compass Therapeutics, Inc. on April 14, 2021. The filing discloses the adoption of new employment agreements for key executive officers, specifically the Chief Executive Officer and the President and Chief Operating Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The primary material change reported is the formalization of employment terms for two named executive officers effective April 14, 2021:
- Thomas J. Schuetz, M.D., Ph.D. (CEO): Entered into an "at-will" employment agreement. He continues to receive equity in lieu of cash base salary and bonus for fiscal year 2021, with a nominal salary covering medical insurance costs. Severance for termination without cause or resignation for good reason includes $500,000 and up to 12 months of COBRA premiums. Full acceleration of unvested stock awards occurs if termination occurs within 12 months of a change of control.
- Vered Bisker-Leib, Ph.D. (President and COO): Entered into an "at-will" employment agreement superseding a 2017 offer letter. Her annual base salary is set at $400,000 with a target annual bonus of 40% of base salary. Severance for termination without cause or resignation for good reason includes 12 months of base salary and up to 12 months of COBRA premiums. Full acceleration of unvested stock awards occurs if termination occurs within 12 months of a change of control.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance or operational strategy. The primary risk disclosed relates to potential "excess parachute payments" under Section 280G of the Internal Revenue Code; both agreements include "gross-up" provisions to ensure executives receive the greater of the full payment or the reduced amount after excise tax adjustments. Severance benefits are contingent upon the executives providing a release of claims.
Investor Verification Checklist
- Verify the specific definitions of "cause" and "good reason" in the attached Exhibits 10.1 and 10.2 to understand termination triggers.
- Confirm the total value of outstanding unvested stock-based awards held by Dr. Schuetz and Dr. Bisker-Leib to assess potential acceleration liabilities.
- Review the company's cash position to ensure it can meet the $500,000 severance obligation for the CEO and the 12-month salary obligation for the COO if triggered.
- Check subsequent filings for any changes to the CEO's compensation structure, as he is currently receiving equity in lieu of cash.